Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.

December 06, 2024

Vol.50 No.45

Health Equity

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.

November 22, 2024

Vol.50 No.44

By McKenzie Prillaman

In Brief

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.

November 22, 2024

Vol.50 No.44

In the Archives

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Jose and Irma Russo dedicated their careers to investigating breast cancer, its causes, and potential prevention measures.

September 27, 2024

Vol.50 No.36

Clinical Trials & Tribulations

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.

September 06, 2024

Vol.50 No.33

By Rebecca Sutphen, Sue Friedman and Jon Florin

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

YOU MAY BE INTERESTED IN

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Renew today!

Subscriber content

Never miss an issue!

Login

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

YOU MAY BE INTERESTED IN

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Never miss an issue!

Login

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?